Recursion Pharmaceuticals (NASDAQ:RXRX) Share Price Crosses Below 50 Day Moving Average – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $3.76 and traded as low as $3.65. Recursion Pharmaceuticals shares last traded at $3.68, with a volume of 20,684,013 shares changing hands.

Recursion Pharmaceuticals News Roundup

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: New Phase 2 results for REC-4881 showed durable reductions in polyp burden in patients with familial adenomatous polyposis, including larger, higher-risk polyps and activity across the gastrointestinal tract. REC-4881 Phase 2 results
• Positive Sentiment: Third-quarter revenue climbed 258.5% to $18.55 million, above the $14.81 million consensus, helped by a $10 million Sanofi milestone payment. The loss of $0.22 per share was narrower than Zacks’ $0.24 estimate and the year-earlier $0.36 loss. Q3 results and Sanofi milestone
• Positive Sentiment: Recursion said its cash runway is expected to extend into 2029, easing near-term financing concerns. The company also appointed pharmaceutical veteran Fred Hassan as board chair. Q3 financial and business update
• Negative Sentiment: The REC-4881 registrational study is targeted for the second half of 2027, leaving a lengthy path before potential pivotal-trial progress. Recursion also remains loss-making, and valuation commentary has raised downside concerns. REC-4881 study timing and cash runway

Wall Street Analyst Weigh In

A number of brokerages have commented on RXRX. Morgan Stanley set a $5.90 price target on Recursion Pharmaceuticals in a research note on Friday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.18.

Recursion Pharmaceuticals Trading Down 3.9%

The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The firm’s 50 day moving average price is $3.76 and its 200 day moving average price is $3.53. The stock has a market capitalization of $1.97 billion, a P/E ratio of -4.09 and a beta of 1.15.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative return on equity of 46.47% and a negative net margin of 697.15%. The company had revenue of $18.55 million for the quarter, compared to analysts’ expectations of $14.81 million. During the same period last year, the firm earned ($0.36) earnings per share. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the sale, the director directly owned 162,156 shares in the company, valued at approximately $810,780. This trade represents a 13.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total value of $242,000.00. Following the transaction, the director directly owned 6,108,287 shares in the company, valued at $29,564,109.08. This trade represents a 0.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 127,408 shares of company stock worth $546,076. 6.65% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. First Trust Advisors LP grew its holdings in shares of Recursion Pharmaceuticals by 15.2% during the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after acquiring an additional 344,035 shares during the period. Bank of America Corp DE lifted its stake in shares of Recursion Pharmaceuticals by 18.2% in the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after purchasing an additional 384,486 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $7,370,000. Bank of New York Mellon Corp lifted its stake in shares of Recursion Pharmaceuticals by 29.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock valued at $4,490,000 after purchasing an additional 331,048 shares during the period. Finally, Hsbc Holdings PLC boosted its position in shares of Recursion Pharmaceuticals by 537.3% during the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock valued at $3,367,000 after purchasing an additional 689,903 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.